Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy

Novel insights into the function and dynamics of extracellular matrix in liver fibrosis

(2015) Morten A. Karsdal et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes

(2015) Aijaz Ahmed et al.   Clinical Gastroenterology and Hepatology

Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014

(2015) Natalie J. Torok et al.   HEPATOLOGY

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop

(2015) Arun J. Sanyal et al.   HEPATOLOGY

Nonalcoholic Fatty Liver Disease

(2015) Mary E. Rinella   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Current efforts and trends in the treatment of NASH

(2015) Vlad Ratziu et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Hepatitis C

(2015) Daniel P Webster et al.   LANCET

Genetics, diagnostics and therapeutic advances in NAFLD

(2015) Mary E. Rinella et al.   Nature Reviews Gastroenterology & Hepatology

Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients

(2015) Mette J. Nielsen et al.   PLoS One

Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance

(2015) Per Stål   WORLD JOURNAL OF GASTROENTEROLOGY

PPARγand the Innate Immune System Mediate the Resolution of Inflammation

(2015) Amanda Croasdell et al.   PPAR Research

Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C

(2014) Mette J. Nielsen et al.   LIVER INTERNATIONAL

Pioglitazone Treatment Reduces Adipose Tissue Inflammation through Reduction of Mast Cell and Macrophage Number and by Improving Vascularity

(2014) Michael Spencer et al.   PLoS One

Evolving therapies for liver fibrosis

(2013) Detlef Schuppan et al.   JOURNAL OF CLINICAL INVESTIGATION

Therapy for Fibrotic Diseases: Nearing the Starting Line

(2013) S. L. Friedman et al.   Science Translational Medicine

Peroxisome Proliferator-activated Receptor-γ Activation Enhances Insulin-stimulated Glucose Disposal by Reducingped/pea-15Gene Expression in Skeletal Muscle Cells

(2012) Paola Ungaro et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

(2011) Kim Henriksen et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection

(2009) John McHutchison et al.   GASTROENTEROLOGY

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

(2009) Vlad Ratziu et al.   HEPATOLOGY

Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease

(2008) Don C. Rockey   Clinics in Liver Disease

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

(2008) Vlad Ratziu et al.   GASTROENTEROLOGY

Liver cirrhosis

(2008) Detlef Schuppan et al.   LANCET